CDK-a

CDK-a is a preclinical-stage small molecule inhibitor being developed by PRISM BioLab for the treatment of oncology. The compound is designed using PRISM's proprietary PepMetics technology, which creates small molecules that mimic the alpha-helix structure of proteins to disrupt protein-protein interactions (PPIs). Specifically, CDK-a is intended to inhibit the kinase activity of a cyclin-dependent kinase (CDK) and/or disrupt the interaction between the CDK and its cyclin partner. By targeting these cell cycle regulators, the drug aims to arrest tumor cell proliferation. As of 2024, the program is in the hit-to-lead phase of preclinical development.